Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Universal human papillomavirus genotyping by the digene HPV Genotyping RH and LQ Tests.

Geraets DT, Lenselink CH, Bekkers RL, van Doorn LJ, Quint WG, Melchers WJ.

J Clin Virol. 2011 Apr;50(4):276-80. doi: 10.1016/j.jcv.2010.12.011. Epub 2011 Feb 5.

PMID:
21296612
2.

High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.

Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, van Doorn LJ, Quint WG.

J Clin Virol. 2009 Nov;46 Suppl 3:S21-6. doi: 10.1016/S1386-6532(09)70297-5.

PMID:
20129070
3.

High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.

Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG.

J Clin Virol. 2009 Nov;46 Suppl 3:S16-20. doi: 10.1016/S1386-6532(09)70296-3.

PMID:
20129069
4.

Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.

Halfon P, Trepo E, Antoniotti G, Bernot C, Cart-Lamy P, Khiri H, Thibaud D, Marron J, Martineau A, Pénaranda G, Benmoura D, Blanc B; RBML (Réseau de Biologie Moléculaire Libérale).

J Clin Microbiol. 2007 Feb;45(2):313-6. Epub 2006 Nov 22.

5.
6.

Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M.

J Clin Microbiol. 2006 Jun;44(6):2141-6.

7.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
8.

A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.

Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M.

Cancer Causes Control. 2010 Oct;21(10):1693-700. doi: 10.1007/s10552-010-9598-2. Epub 2010 Jul 9.

PMID:
20617376
9.

Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.

Wong AK, Chan RC, Nichols WS, Bose S.

J Clin Microbiol. 2008 Mar;46(3):869-75. doi: 10.1128/JCM.01424-07. Epub 2008 Jan 3.

10.

HPV testing in cervical screening.

Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH.

Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):253-66. Epub 2005 Dec 13. Review.

PMID:
16359926
11.

Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.

Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C.

J Virol Methods. 2009 Mar;156(1-2):77-83. doi: 10.1016/j.jviromet.2008.11.002. Epub 2008 Dec 17.

PMID:
19041893
12.

Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening.

García-Sierra N, Martró E, Castellà E, Llatjós M, Tarrats A, Bascuñana E, Díaz R, Carrasco M, Sirera G, Matas L, Ausina V.

J Clin Microbiol. 2009 Jul;47(7):2165-9. doi: 10.1128/JCM.00402-09. Epub 2009 May 13.

13.

Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes.

Seme K, Lepej SZ, Lunar MM, Iscić-Bes J, Planinić A, Kocjan BJ, Vince A, Poljak M.

J Clin Virol. 2009 Oct;46(2):176-9. doi: 10.1016/j.jcv.2009.07.017. Epub 2009 Aug 15.

PMID:
19683958
14.

Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.

Nishino HT, Tambouret RH, Wilbur DC.

Cancer Cytopathol. 2011 Aug 25;119(4):219-27. doi: 10.1002/cncy.20161. Epub 2011 Jun 29. Review.

15.

Validation of high-risk HPV tests for primary cervical screening.

Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ.

J Clin Virol. 2009 Nov;46 Suppl 3:S1-4. doi: 10.1016/S1386-6532(09)00540-X.

PMID:
20129067
16.

Patient safety and the next generation of HPV DNA tests.

Lee SH.

Am J Clin Pathol. 2011 Mar;135(3):481; author reply 482-3. doi: 10.1309/AJCP96UJOYHHOCJU. No abstract available.

PMID:
21350106
18.

[High-risk human papilloma virus DNA detection kit (cervista HPV HR) should be highly validated clinically in cervical cancer screening programs].

Zhao J, Zhang XG, Chen R, Bi H, Wang X, Liu GW, Yao DX, Zong Y, Liao QP.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Apr;25(2):149-51. Chinese.

PMID:
21863645
19.
20.

Type-specific human papillomavirus DNA testing with the genotyping array: a comparison of cervical and vaginal sampling.

Twu NF, Yen MS, Lau HY, Chen YJ, Yu BK, Lin CY.

Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):96-100. doi: 10.1016/j.ejogrb.2010.12.023. Epub 2011 Feb 1.

PMID:
21288625

Supplemental Content

Support Center